pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
333
stories
24d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
24d
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
24d
GSK partner Hansoh reports another phase 3 win for priority ADC
fiercebiotech
24d
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
25d
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
biopharma dive
25d
Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pill
endpoints
25d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
25d
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
25d
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
25d
Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease
endpoints
25d
Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B
endpoints
25d
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
25d
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
fiercebiotech
25d
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
fiercebiotech
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
28d
Amgen sheds around 40 staffers amid continuing struggles
fiercebiotech
28d
Sanofi halts development of troubled immune drug in eczema
biopharma dive
28d
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
28d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
28d
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
28d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
28d
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
28d
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
endpoints
28d
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
fiercebiotech
29d
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
biospace
29d
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
STAT+: Pharma tries to tamp down broad China restrictions
stat
Jul 22, 26
Summit reports two-year survival data for Western patients, though context lacking
endpoints
Jul 22, 26
Celldex scraps antibody in prurigo nodularis after Phase 2 flop
endpoints
← prev
page 5 of 12
next →
